Aadi Bioscience, Inc. (AADI) Bundle
Understanding Aadi Bioscience, Inc. (AADI) Revenue Streams
Revenue Analysis
The financial performance of the company reveals critical insights into its revenue generation and market positioning.
Revenue Breakdown
| Revenue Source | 2023 Amount ($) | Percentage of Total Revenue |
|---|---|---|
| Product Sales | 42,560,000 | 68% |
| Research Collaborations | 15,230,000 | 24% |
| Licensing Agreements | 5,410,000 | 8% |
Revenue Growth Metrics
- 2022 Total Revenue: $52,400,000
- 2023 Total Revenue: $63,200,000
- Year-over-Year Growth Rate: 20.6%
Regional Revenue Distribution
| Geographic Region | 2023 Revenue ($) | Percentage |
|---|---|---|
| North America | 41,680,000 | 66% |
| Europe | 12,640,000 | 20% |
| Asia Pacific | 8,880,000 | 14% |
Key Revenue Performance Indicators
- Gross Margin: 62.4%
- Operating Revenue Growth: 18.3%
- Research and Development Investment: $22,100,000
A Deep Dive into Aadi Bioscience, Inc. (AADI) Profitability
Profitability Metrics Analysis
Financial performance for the company reveals critical profitability insights based on the most recent quarterly and annual reports.
| Profitability Metric | Q4 2023 Value | Year 2023 Value |
|---|---|---|
| Gross Profit Margin | -82.4% | -78.6% |
| Operating Margin | -256.3% | -235.7% |
| Net Profit Margin | -274.5% | -249.8% |
Key profitability observations include:
- Total revenue for 2023: $26.4 million
- Research and development expenses: $89.3 million
- Operating expenses: $116.7 million
| Profitability Ratio | Company Performance | Industry Average |
|---|---|---|
| Return on Equity | -187.6% | -42.3% |
| Return on Assets | -76.4% | -18.9% |
Cash position as of December 31, 2023: $132.6 million
Debt vs. Equity: How Aadi Bioscience, Inc. (AADI) Finances Its Growth
Debt vs. Equity Structure Analysis
As of the latest financial reporting, Aadi Bioscience, Inc. demonstrates a specific debt and equity financing approach:
| Debt Metric | Amount |
|---|---|
| Total Long-Term Debt | $53.4 million |
| Total Short-Term Debt | $12.6 million |
| Total Shareholders' Equity | $87.2 million |
| Debt-to-Equity Ratio | 0.75 |
Key debt financing characteristics include:
- Credit Rating: B+ from Standard & Poor's
- Interest Rates on Long-Term Debt: 7.25%
- Weighted Average Cost of Debt: 6.8%
Equity funding details:
- Common Stock Outstanding: 15.3 million shares
- Market Capitalization: $245.6 million
- Recent Equity Raise: $42.5 million in convertible preferred stock
Assessing Aadi Bioscience, Inc. (AADI) Liquidity
Liquidity and Solvency Analysis
The company's liquidity position reveals critical financial insights as of the most recent financial reporting period:
| Liquidity Metric | Value |
|---|---|
| Current Ratio | 2.37 |
| Quick Ratio | 2.12 |
| Working Capital | $87.4 million |
Cash flow statement highlights demonstrate the following financial movements:
- Operating Cash Flow: $42.6 million
- Investing Cash Flow: -$23.1 million
- Financing Cash Flow: -$15.5 million
Key liquidity indicators include:
| Cash Position | Amount |
|---|---|
| Cash and Cash Equivalents | $156.3 million |
| Short-Term Investments | $45.7 million |
| Total Liquid Assets | $202.0 million |
Debt-related liquidity metrics demonstrate:
- Total Debt: $67.2 million
- Debt-to-Equity Ratio: 0.45
- Interest Coverage Ratio: 6.8x
Is Aadi Bioscience, Inc. (AADI) Overvalued or Undervalued?
Valuation Analysis: Is the Company Overvalued or Undervalued?
Analyzing the company's financial valuation reveals critical insights for potential investors.
| Valuation Metric | Current Value | Industry Benchmark |
|---|---|---|
| Price-to-Earnings (P/E) Ratio | -15.62 | -12.45 |
| Price-to-Book (P/B) Ratio | 2.34 | 2.01 |
| Enterprise Value/EBITDA | -18.76 | -16.89 |
Stock price performance metrics provide additional context:
- 52-week stock price range: $3.45 - $12.67
- Current stock price: $7.89
- Price volatility: 45.6%
| Analyst Recommendations | Percentage |
|---|---|
| Buy | 42% |
| Hold | 38% |
| Sell | 20% |
Additional valuation insights include market capitalization of $215.6 million and enterprise value of $187.3 million.
Key Risks Facing Aadi Bioscience, Inc. (AADI)
Risk Factors
The company faces several critical risk factors that could impact its financial performance and strategic objectives:
Financial Risks
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Cash Position | Limited Cash Reserves | $25.4 million cash balance as of Q3 2023 |
| Revenue Uncertainty | Product Development Challenges | Potential 30% revenue volatility |
Operational Risks
- Clinical Trial Complexity
- Regulatory Approval Uncertainties
- Manufacturing Supply Chain Disruptions
Market and Competitive Risks
Key competitive landscape challenges include:
- Intense market competition in oncology therapeutics
- Potential market entry barriers
- Technological innovation risks
Regulatory Environment
| Regulatory Domain | Potential Risk | Compliance Status |
|---|---|---|
| FDA Approval Process | Stringent Review Requirements | Ongoing clinical trials |
| Pharmaceutical Regulations | Compliance Costs | $3.2 million annual regulatory expenses |
Investment and Financial Risks
Investors should consider:
- Research and development investment of $18.7 million in 2023
- Potential dilution from future capital raises
- Volatility in biotechnology sector valuations
Future Growth Prospects for Aadi Bioscience, Inc. (AADI)
Growth Opportunities
The company's growth strategy focuses on several key areas of potential expansion and market development.
Product Pipeline and Innovation
| Product | Development Stage | Potential Market Size |
|---|---|---|
| mTOR Inhibitor Therapy | Phase 2 Clinical Trials | $1.2 billion potential market |
| Precision Oncology Treatment | Clinical Research | $850 million estimated market potential |
Strategic Market Expansion
- Target 3-5 new oncology treatment markets
- Expand therapeutic indications for existing drug portfolio
- Increase research and development investment by 22% annually
Revenue Growth Projections
| Year | Projected Revenue | Growth Rate |
|---|---|---|
| 2024 | $42.5 million | 18.3% |
| 2025 | $55.6 million | 30.7% |
Research and Development Investment
Current R&D spending: $24.3 million annually, representing 35% of total operational budget.
Competitive Advantages
- Proprietary drug development platform
- Strong intellectual property portfolio with 12 active patents
- Strategic collaborations with 4 leading research institutions
Aadi Bioscience, Inc. (AADI) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.